环氧合酶2在食管恶性肿瘤治疗中的研究进展  

Research progress of cyclooxygenase-2 in the treatment of esophageal malignant tumors

作　　者：沙闯 李忠诚[1] Sha Chuang;Li Zhongcheng(Department of Thoracic Surgery,Qinghai University Affiliated Hospital,Xining 810000,China)

机构地区：[1]青海大学附属医院胸外科,西宁810000

出　　处：《中国医药》2023年第4期602-606,共5页China Medicine

摘　　要：食管恶性肿瘤是目前世界第八大恶性肿瘤,近年来,针对食管恶性肿瘤的分子靶向研究不单单停留在酪氨酸激酶抑制剂或抗血管生成的靶向治疗,关于环氧合酶特别是环氧合酶2亚型在食管恶性肿瘤中高表达的研究也越来越多,大量的研究证实环氧合酶2的高表达与食管恶性肿瘤的发病密切相关,应用选择性环氧合酶2靶向抑制剂治疗食管恶性肿瘤的可行性日益凸显。本文综述了环氧合酶2及其典型靶向抑制剂在食管恶性肿瘤治疗中的研究进展,以期为食管恶性肿瘤患者增加治疗方案提供参考。Esophageal malignant tumors are currently the eighth largest malignant tumors in the world.In recent years,the molecular targeting researches on esophageal malignant tumors are not only focused on tyrosine kinase inhibitors or anti-angiogenic targeted therapy,but also on the high expression of cyclooxygenase,especially cyclooxygenase-2 subtype,in esophageal malignant tumors.Amount of studies confirmed that the high expression of cyclooxygenase-2 is closely related to the pathogenesis of esophageal malignant tumors.The feasibility of using selective cyclooxygenase-2 targeted inhibitors in the treatment of esophageal malignant tumors has become increasingly prominent.This article reviews the research progress of cyclooxygenase-2 and its typical targeted inhibitors in the treatment of esophageal malignant tumors,in order to provide reference for the treatment of patients with esophageal malignant tumors.

关 键 词：食管恶性肿瘤 环氧合酶2 非甾体抗炎药 微小RNA 

分 类 号：R735.1[医药卫生—肿瘤]